Indications for: XOPENEX HFA
Adults and Children:
<4yrs: not established. ≥4yrs: 2 inh every 4–6hrs; or 1 inh every 4hrs may suffice.
XOPENEX HFA Warnings/Precautions:
Do not exceed recommended dose. Monitor for increased need; if inadequate control, reevaluate and consider adding an antiinflammatory (eg, corticosteroids). Sensitivity to sympathomimetics. Discontinue if paradoxical bronchospasm, cardiovascular effects, or hypersensitivity reactions occur. Cardiovascular disorders (esp. coronary insufficiency, arrhythmias, hypertension). Seizure disorders. Diabetes. Hyperthyroidism. Hypokalemia. Renal impairment; monitor (esp. in elderly). Elderly. Labor & delivery. Pregnancy. Nursing mothers.
XOPENEX HFA Classification:
XOPENEX HFA Interactions:
Avoid within 2 weeks of MAOIs, tricyclic antidepressants. Avoid other short-acting sympathomimetic aerosol bronchodilators, epinephrine. Antagonized by β-blockers. Caution with other drugs that may lower serum potassium (eg, diuretics). Monitor digoxin.
Accidental injury, bronchitis, dizziness, pharyngitis, rhinitis, vomiting, palpitations, chest pain, tachycardia, headache, tremor, nervousness.
Generic Drug Availability:
Vials (YES); HFA (NO)
Inhaler w. actuator (200 inh)—15g; Soln 0.31mg/3mL, 0.63mg/3mL, 1.25mg/3mL—24 vials; Concentrate 1.25mg/0.5mL—30 vials